OGN Stock Chart & Stats
$225.00
$0.00(0.00%)
At close: 4:00 PM EDT
$225.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$106.15 - $270.99
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$61.63B
Enterprise Value$11.08K
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$8.55B
Price to Earnings (P/E)16.9
Beta-0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding262,609,440
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.47
Price to Sales (P/S)0.30
P/FCF Ratio3.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharma FranchiseOrganon’s business spans women’s health, biosimilars and established off‑patent brands, providing multiple revenue engines. This diversification reduces single‑product concentration risk, helps stabilize cash flows across market cycles and supports resilience during therapeutic or regional headwinds.
Historically Positive Cash GenerationOperating and free cash flow have been consistently positive historically and free cash flow typically exceeded net income, indicating earnings quality is backed by cash. Durable cash conversion supports funding operations, servicing debt, and potential reinvestment or divestiture flexibility over the medium term.
Merger Clears Major Hurdle; Synergy DisclosureShareholder approval and detailed supplemental disclosures (including $700m estimated cost synergies) materially reduce deal execution uncertainty. If realized, these synergies could structurally improve margins, lower SG&A/ procurement costs and accelerate integration benefits under Sun Pharma ownership.
Bears Say
Very High Financial LeverageExtremely high debt relative to equity and historically negative book equity materially amplify financial risk. Leverage increases interest burden and reduces buffer for operational shocks, constrains strategic flexibility and makes results more sensitive to modest revenue or margin deterioration.
Sharp Revenue Decline And Thin Net MarginsA 25.8% TTM revenue decline combined with a low ~4% net margin signals loss of scale or pricing pressure versus prior periods. Persistent top‑line weakness undermines operating leverage, pressures investment in R&D and commercial efforts, and makes margin recovery harder absent clear revenue stabilization.
Material Free Cash Flow DeteriorationA ~60% decline in trailing free cash flow and modest coverage ratios reduce financial flexibility to service debt, fund integration or reinvestment. The drop weakens the company’s cushion against operational setbacks and elevates refinancing and execution risk during the merger and post‑integration period.
Organon News
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $106.15 and its highest was $270.99 in the past 12 months.
What is Organon’s market cap?
Organon’s market cap is $61.63B.
When is Organon’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Organon’s earnings last quarter?
Currently, no data Available
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Overvalued.
Does Organon pay dividends?
Organon does not currently pay dividends.
What is Organon’s EPS estimate?
Organon’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Organon have?
Organon has 262,609,440 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Organon?
Currently, no hedge funds are holding shares in MX:OGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MX:OGN Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.45%
12-Months-Change
Fundamentals
Return on Equity
0.65%
Trailing 12-Months
Asset Growth
-2.39%
Trailing 12-Months
Company Description
Organon
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.